<DOC>
	<DOC>NCT00380692</DOC>
	<brief_summary>The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).</brief_summary>
	<brief_title>Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria (most important): ASD (autistic disorder or Asperger's disorder or Pervasive Developmental Disorder Not Otherwise Specified [PDD NOS]) Criteria A through D for AttentionDeficit/Hyperactivity Disorder (ADHD) At least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the ADHD Rating ScaleIVParent Version Intelligence quotient (IQ) score &gt; 60 Exclusion Criteria (most important): weight under 20 kg Patients who meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSMIVTR) criteria for ASD other than Autistic Disorder, PDDNOS or Asperger's Disorder;history of Bipolar I or II disorder, schizophrenia, another psychotic disorder, substance abuse;Have a significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, or seizure disorder identified by history, physical examination, or laboratory tests; Patients who have taken (or are currently taking) anticonvulsants for seizure control. patients at serious suicidal risk. Contraindication to the use of atomoxetine Patients who in the investigator's judgment are likely to need psychotropic medications apart from the drug. Patients who at any time during Study Period II are likely to begin a structured psychotherapy, likely to require hospitalization (i.e. inpatient treatment) or likely to be dismissed from inpatient treatment. Psychotherapy (including hospitalization) initiated at least 2 months prior to study participation is acceptable; however, after study participation has begun, only during Study Period III supportive or educational therapy is permitted.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>